Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease

Second-generation anti-amyloid monoclonal antibodies are emerging as a viable therapeutic option for individuals with prodromal and mild dementia due to Alzheimer's disease (AD). Passive immunotherapy with aducanumab (Aduhelm), lecanemab, donanemab, and gantenerumab all lower CNS amyloid (Aβ) b...

Descripción completa

Detalles Bibliográficos
Autores principales: Withington, Charles G., Turner, R. Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985815/
https://www.ncbi.nlm.nih.gov/pubmed/35401412
http://dx.doi.org/10.3389/fneur.2022.862369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985815/
https://www.ncbi.nlm.nih.gov/pubmed/35401412
http://dx.doi.org/10.3389/fneur.2022.862369

Ejemplares similares